BlinkLab

The Pharmacology of Human Decision Making Study with Monash University

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for neurological disorders, is pleased to announce a new study to run in partnership with Monash University. The study will evaluate BlinkLab as a medical device able to monitor the therapeutic effects of ketamine on cognitive processes whereby sensory information is converted into decision making. In the future, results from this study can help facilitate cognitive behavioural therapy outcomes in patients with psychiatric conditions such as depression, schizophrenia, epilepsy, and post-traumatic stress disorder (PTSD).


Highlights

  • Study provides a unique opportunity to discover the building blocks of cognition with the potential to transform our understanding of a range of clinical conditions including depression, schizophrenia, epilepsy, PTSD.
  • Potential to demonstrate that drugs targeting glutamatergic neurotransmission can treat some aspects of psychiatric disease symptomology or improve the efficacy of cognitive behavioural therapy.
  • Evaluates ability of BlinkLab tests to be used as a tool to measure pharmacological effects of existing and novel therapeutic agents.

Significance of the Study

Perceptual decision-making is a fundamental cognitive process where sensory information is transformed into meaningful interpretations of the environment, guiding our actions. This field has flourished through the integration of neuroscience and mathematical modelling , providing a robust framework for investigating the neural mechanisms involved. The core idea is that decisions are based on the accumulation of sensory evidence until a decision threshold is reached. These advancements offer a unique opportunity to uncover the fundamental components of cognition and have the potential to revolutionise our understanding of various clinical conditions. By characterising underlying mechanistic abnormalities, refining clinical classifications, and identifying intervention targets, this research holds promise for significant clinical advancements and new therapies for a variety of psychiatric and neurodevelopmental conditions.

The study, conducted by the School of Psychological Sciences at Monash University will investigate the impact of glutamate challenge on perceptual decision making (including behavioural performance, sensorimotor gating) by administering ketamine while participants perform a prepulse inhibition test using BlinkLab application.

The study will be able to demonstrate whether administration of ketamine can disrupt basic sensory encoding mechanisms, which will be detectable in reduced prepulse inhibition.

Study Design

The study will recruit up to 35 healthy adults between 18-55 years old. Each participant will complete 3 testing sessions after ketamine administration. Their participation is expected to take 4-5 weeks per subject.

Terms of the Collaboration Agreement (“Agreement”)

  • Responsibilities: BlinkLab will provide access to its technology, data and shall facilitate the use of its platform during the term of the Agreement.
  • Financial arrangements: None at the date of signing (to be determined via mutual agreement in the future and in a separate agreement).
  • Intellectual Property: Each party will retain all right, title and interest in and to its background intellectual property (copyright, trademarks, designs, know how, patents, plant varieties, confidential information and all other intellectual property as defined in article 2 of the Convention establishing the World Intellectual Property Organization 1967). Any project IP (generated through the study) will be owned by Monash University.
  • Term: Date of signature by the last party to sign (5 August 2024), until completion of the Research Project as communicated by Monash.
  • Termination: Either party may terminate this Agreement by giving between 5 and 20 days written notice (at the terminating party’s election) to the other party if the other party commits a material breach of the Agreement and does not remedy that breach within 10 days after receiving notice requiring them to do so. Monash may terminate this agreement with immediate effect by giving written notice to BlinkLab.
  • Confidentiality: Standard confidentiality terms for an agreement of this nature included.

This announcement has been approved by the Board of Directors.


Click here for the full ASX Release

This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

BB1:AU
BlinkLab Limited

BlinkLab Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
BlinkLab Limited

BlinkLab Limited


Keep reading...Show less
BlinkLab

Blinklab Signs Partnership for Clinical Trial with European INTER-PSY, Supporting US and EU Regulatory Approval and Future Market Adoption

Partnership with INTER-PSY to run a prospective clinical trial on early-diagnosis of autism.

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), an innovative digital healthcare company developing smartphone-based AI powered sensory assessments to aid in the diagnosis of neurodevelopmental conditions including autism and ADHD, is pleased to announce a research and clinical partnership with the INTER-PSY (“Agreement”) in the Netherlands (https://interpsy.interpsygroep.nl/).

Keep reading...Show less
AI chip.

Ex-OpenAI Leader Raises US$1 Billion for Safety-focused AI Startup

Safe Superintelligence (SSI), a startup co-founded by former OpenAI Chief Scientist Ilya Sutskever, has secured US$1 billion in seed funding to develop advanced artificial intelligence (AI) systems focused on safety.

Reuters reported that the funding round, led by venture capital firms Andreessen Horowitz, Sequoia Capital, DST Global and SV Angel, has raised the value of the three month old company to an estimated US$5 billion.

The funds will be used to acquire computing power and recruit top engineering and research talent. Currently, SSI has 10 employees and operates out of offices in Palo Alto, California, and Tel Aviv, Israel.

Keep reading...Show less
ChatGPT logo overlayed on human profile.

How to Invest in OpenAI's ChatGPT (Updated 2024)

OpenAI’s ChatGPT is one of the latest technological breakthroughs in the artificial intelligence space. But what is ChatGPT, and can you invest in OpenAI? Read on to learn about its history — including its controversies — how to get investment exposure to OpenAI and other stocks you can buy in the generative AI space.

This emerging technology is representative of a niche subsector of the AI industry known as generative AI — systems that can generate text, images or sounds in response to prompts given by users.

Precedence Research expects the global AI market to grow at a compound annual growth rate (CAGR) of 19 percent to reach US$2.57 trillion by 2032. Just how much of an impact OpenAI’s ChatGPT will have on this space is hard to predict, but S&P Global suggested in December 2023 that the total market revenue of generative AI as a whole will see a CAGR of 57.9 percent through 2028, increasing from US$3.7 billion last year to US$36.36 billion in 2028.

Keep reading...Show less
Artificial intelligence chip.

Tech 5: NVIDIA Shares Latest Results, OpenAI Seeks Billions in New Funding Round

Tech investors were eyeing results from major companies as the last week of August unfolded.

Meanwhile, Bitcoin and Ether prices experienced declines during the five day period, while Google's (NASDAQ:GOOGL) Gemini platform received a boost with the rollout of two new features.

OpenAI also made headlines — it's reportedly in discussions to launch a substantial funding round that could give it the distinction of being the highest-valued artificial intelligence (AI) startup to date.

Keep reading...Show less
OpenAI website.

NVIDIA Eyeing US$100 Million Investment in OpenAI's US$100 Billion Funding Round

Leading chipmaker NVIDIA (NASDAQ:NVDA) is reportedly one of several tech giants considering a significant investment in OpenAI's latest funding round, Bloomberg said on Thursday (August 29).

The funding round, led by Thrive Capital, is expected to value the artificial intelligence (AI) startup at over US$100 billion. NVIDIA is said to be eyeing a US$100 million stake in OpenAI as companies race to get exposure to the AI sector.

Apple (NASDAQ:AAPL) and Microsoft (NASDAQ:MSFT) are also believed to be interested in the capital raising. Microsoft, currently OpenAI’s largest backer, has invested about US$13 billion in the company to date.

Keep reading...Show less
NVIDIA logo.

NVIDIA Q2 Stock Earnings: What Investors Need to Know

All eyes in the investment world were on Nvidia (NASDAQ:NVDA) today (August 28) as the tech giant prepared to release its eagerly anticipated Q2 2025 earnings report after the closing bell.

Amid growing concerns about overvaluation and potential market correction, Nvidia's performance over the last few quarters has captured the attention of investors and analysts alike.

With high stakes and major implications for the broader market, the release of Nvidia's Q2 earnings report is poised to have a substantial impact on the company's trajectory and the tech sector as a whole.

Keep reading...Show less
BlinkLab Limited

BlinkLab Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×